---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-270847"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2021-09-13T23:59:59+00:00"
generated_at: "2026-06-29T04:04:34.797388+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics appoints Norman LaFrance as CMO, effective Dec 8, 2021

## Summary
- Dr. LaFrance will receive $440K base salary, 35% target bonus, and options for 120K shares vesting over 4 years.
- He brings 40 years in nuclear medicine and pharma, previously CMO at Jubilant Pharma Ltd.
- Appointment effective Dec 8, 2021; LaFrance will lead clinical development, regulatory, and medical affairs.
- Severance package includes 12 months salary + target bonus + COBRA premium if terminated without cause.

## SEC filing metadata
- accession: 0001193125-21-270847
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2021-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312521270847/0001193125-21-270847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312521270847/d151447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-270847
- JSON: https://secwatch.observer/filing/0001193125-21-270847.json
- Plain text: https://secwatch.observer/filing/0001193125-21-270847.txt

## Key facts
- Executive change
  Norman LaFrance was appointed as Chief Medical Officer at PLUS THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312521270847/0001193125-21-270847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.